阿斯特拉加林通过抑制老鼠的阿尔多缩酶活性减轻糖尿病白内障
Na Wang1, Deepika Singh2, Qiong Wu1
1Department of Ophthalmology, Shaanxi Eye Hospital, Xi'an People's Hospital (Xi'an Fourth Hospital), Affiliated People's Hospital of Northwest University, Xi'an 710004, Shaanxi Province, China.
International journal of ophthalmology
|August 21, 2023
概括
阿斯塔加林 (AST) 有效抑制阿尔多减少酶 (AR),以预防大鼠糖尿病白内障 (DCs). 这种天然化合物还可以改善抗氧化剂水平和生物化学参数,显示出糖尿病的治疗潜力.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 眼科医生 眼科 眼科
背景情况:
- 糖尿病白内障 (DCs) 是糖尿病的一个重要并发症.
- 阿尔多斯减少酶 (AR) 在糖尿病并发症的发病过程中发挥着关键作用,包括白内障.
- 阿斯特拉加林 (AST) 是一种具有潜在治疗功能的天然黄化合物.
研究的目的:
- 评估阿斯特拉加林 (AST) 在抑制阿尔多减酶 (AR) 活性方面的疗效.
- 在大鼠模型中研究AST对链毒素诱导的糖尿病白内障 (DC) 的保护作用.
主要方法:
- 使用用银河糖处理的山羊透镜进行的ex vivo研究.
- 在体内研究中,涉及链毒素诱导的糖尿病大鼠接受了不同剂量的AST.
- 生物化学参数的评估,包括AR活性,炎症调解剂,细胞因子和抗氧化剂水平 (SOD,CAT,GSH).
主要成果:
- 在糖尿病大鼠中,AST的剂量取决于体重,血中的胰岛素和葡萄糖水平的改善.
- AST抑制了阿尔多减少酶 (AR) 的活性,并减少了银河醇的形成.
- 施用AST会增加抗氧化酶的活性,例如超氧化脱酶 (SOD),催化酶 (CAT) 和谷氨 (GSH).
结论:
- 阿斯塔加林 (AST) 显示出显著的保护作用,防止透镜变暗和聚合物形成,这是糖尿病白内障的关键因素.
- AST抑制阿尔多减少酶 (AR) 和增强抗氧化防御的能力表明它作为治疗糖尿病并发症的治疗剂的潜力.
相关概念视频
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
205
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
205
01:23Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
01:24Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
01:27Open Angle Glaucoma: Treatment
477
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
477